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TransplantatABSTRACT
Purpose. To relieve the chronic shortage of donor kidneys, we conducted a prospective
kidney transplantation trial using kidneys removed from 10 unrelated patients (51 to
79 years of age) who had undergone nephrectomy for small renal cell carcinoma (1.5 to
3.9 cm) of low-to-moderate complexity based on RENAL (radius, exophytic/endophytic
properties, nearness of tumor to the collecting system or sinus in millimeters, anterior/
posterior location relative to polar lines) nephrometry (objective description helpful for
operative indication and planning).
Methods. Donors were selected from among 15 patients who opted to undergo ne-
phrectomy for small renal cell carcinoma. A total of 76 dialysis patients 34 to 85 years of
age who agreed to undergo restored kidney transplantation were recruited as transplant
candidates.
Results. In stage 1 (5 cases), high-risk patients were selected without human leukocyte
antigen testing, and accelerated acute rejection occurred in 4 of 5 recipients. This trial
was subsequently extended with human leukocyte antigen testing, and an additional
5 patients were enrolled in stage 2. Eight recipients, including 4 recipients with a history
of renal transplantation, experienced rejection; 1 patient resumed dialysis 35 months
after transplantation. The most recent serum creatinine levels ranged from 1.10 to
3.19 mg/dL in the 9 recipients with functioning grafts and from 0.84 to 4.68 mg/dL in
the 10 donors. No tumor recurrence was noted at 32 to 58 months after surgery in
either the recipients or the donors.
Conclusions. Restored kidney transplantation using kidneys with a small renal tumor
seems suitable for carefully selected high-risk recipients and, in particular, elderly kidneys
can also function well. Avoiding cancer transmission, fair recipient selection, close follow-
up, and a well-organized tracking system warrant further study.This trial was ﬁnancially supported by the Tokushukai Medical
Group (the procedure and follow-up cost was approximately
$100,000 for each case).
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E-mail: yoshihide.ogawa@tokushukai.jpTHE LONGSTANDING shortage of donor kidneys is achallenging problem in many countries worldwide. In
1995, the transplantation of kidneys following ex vivo
resection of small tumors was ﬁrst reported in 14 recipients
without any recurrence (Penn I) [1]. Based on that experi-
ence, Buell et al. concluded that kidneys with small (0.5 to
4 cm in diameter), incidental renal cell carcinomas (RCCs) of
low histological grade could be used for transplantation afterAuthors. Published by Elsevier Inc. This is an open
le under the CC BY-NC-ND license (http://
mons.org/licenses/by-nc-nd/4.0/).
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[2]. Mannami et al. reported the results of restored kidney
transplantation in 42 patients, including 8 kidneys obtained
after nephrectomy for RCC, among a variety of efforts to
expand the donor kidney pool for high-risk recipients [3]. In
2008, Nicol et al. reported an additional 43 cases of restored
kidney transplantation after nephrectomy for renal tumors,
including 31 cases of RCC (diameter <3 cm) [4]. The
transplantation of kidneys removed to treat small RCCs has
been reported by several investigators and performed in a
total of 97 patients to date [5]. The transmission of malig-
nancy with the transplanted kidney has been rare (0.015% to
1%) in recent clinical practice given stringent donor criteria
[6e8]. Meticulous surgical techniques and careful patholog-
ical examinations are also essential [9]. According to a report
by the Amsterdam Forum, a history of malignancy (including
RCC) typically excludes living-related kidney donation [10].
To optimize organ usage, Nalesnik et al. recently evaluated
the risk of transmitting certain cancers, such as solitary, well-
differentiated (Fuhrman nuclear grade I-II) RCCs [11e13].
The suggested risk categories (1 cm in diameter for minimal
risk, 1 to 2.5 cm for low risk, and 4 to 7 cm for intermediate
risk) have been incorporated with clinical considerations into
several guidelines [14], including the European Association
of Urology guidelines for renal transplantation [15],
UK guidelines [16], the World Health Organization Notify
project [17], the ATOS group in Spain [18], and the Kidney
Health Australia Caring for Australasians with Renal
Impairment [19]. The Notify project also warned of special
cases of unusual transmission and recurrence; thus, the risks
associated with speciﬁc case series should be reported.
Despite differences in the interpretation of the risk cate-
gories, all of these guidelines unanimously accept that renal
tumors <4 cm in diameter (stage pT1a) with a Fuhrman
grade of I to II pose either a nonstandard or a standard
risk [17].
Although the risk of transmitting malignancy is low with
careful assessment of donor kidneys, all recipients must be
informed of this risk [20,21]. Based on a comparison of the
risk of death while on dialysis with the risk of developing
cancer from a transplanted kidney [22,23], high-risk patients
may be the most appropriate candidates for the trans-
plantation of kidneys removed to treat small RCCs [24e26].
More than 80% of small renal tumors (<4 cm) are treated
by nephrectomy in Japan, and approximately 2000 kidneys
are discarded after this process every year [27]. Deceased
kidney donors are scarce in Japan, with only 150 to
200 deceased renal allografts available annually. Living-
related kidney transplantation is primarily performed, with
kidneys from 1389 donors used in 2011 [28,29]. A total of
13,389 of 309,946 dialysis patients are registered with the
Japan Organ Transplant Network as seeking renal trans-
plantation [28,30]. The mean waiting time for kidney
transplantation is 14 years and 6 months, leading to an in-
crease in transplant tourism in Japan [31e34]. Altruistic
donation and paired kidney exchange programs are not
currently accepted in Japan. In addition, the transplantationof kidneys with benign or malignant diseases was banned by
the Japanese government in 2007 with the exception of
transplants conducted as part of clinical trials (the medical
fee must be paid by the hospital).
After carefully examining the literature on the suitability
of discarded kidneys for transplantation [2e4,24,25,35,36],
we focused on the use of kidneys with small RCCs (<4 cm in
diameter on imaging studies) out of various disease kidneys,
that is different from the previous study [3]. No prospective
outcome data were available; thus, we conducted a pro-
spective, open clinical trial utilizing 5 kidneys with small
RCCs that were restored and transplanted into 5 unrelated
recipients (stage 1) [37]. This trial was subsequently
extended to enroll an additional 5 patients (stage 2). Here,
we report the ﬁrst prospective clinical trial of restored kid-
ney transplantation using kidneys with small RCCs guided
by the nephrometry scoring system.PATIENTS AND METHODS
This clinical trial of restored kidney transplantation in unrelated
recipients with a planned enrollment of 5 patients (stage 1) was
approved by the Tokushukai Joint Ethics Committee in July
2009 (registration at US ClinicalTrials.gov: NCT00980317). The
trial was ﬁnancially supported by the Tokushukai Medical Group
(the procedure and follow-up cost was approximately $100,000 for
each case). The primary trial end points included graft function and
tumor transmission up to 1 year after transplantation. The 1-year
glomerular ﬁltration rate is a good predictor of long-term graft
function [38e40]. There is no general consensus about monitoring
patients after treatment for RCC [41]. Tumors typically recur within
2 to 3 years after surgery [42,43]. Secondary end points, including
morbidity and adverse events, also were evaluated up to 1 year after
transplantation. Serious adverse events (SAEs), including post-
operative complications, infections, and rejection, were reported to
the Transplant Ofﬁce and then immediately to the Ministry of
Health, Labor, and Welfare. Two trial committees were organized
and approved by the Tokushukai Joint Ethics Committee: the
Restored Kidney Transplant Committee (composed of 5 members
unconnected to the Tokushukai group) and the nonproﬁt organi-
zation Recipient Selection Committee (composed of 5 third-party
members). The Restored Kidney Transplant Committee deter-
mined whether the kidney donors and recipients met the study in-
clusion criteria. The ﬁrst restored kidney transplant procedure was
successfully performed on December 30, 2009. After the ﬁfth
transplant was performed in August 2010, an extension of the trial
was approved after careful review of the 5 patients treated in stage
1. An additional 5 patients were enrolled because of requests from
dialysis patients on the waiting list. The tenth transplant was per-
formed in February 2012.
Donor Enrollment
Potential donors were recruited among patients who were diag-
nosed as having a single, small RCC (<4 cm in diameter on imaging
studies) at any of the 7 hospitals approved by the Tokushukai Joint
Ethics Committee. Imaging studies were performed to measure the
tumor size and location, and the anatomical tumor features were
classiﬁed according to the RENAL (radius, exophytic/endophytic
properties, nearness of tumor to the collecting system or sinus in
millimeters, anterior/posterior location relative to polar lines)
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dimensions used for an anatomical) classiﬁcation [45], and the
centrality (C) index [46]. The patients were provided information
regarding the nature, size, and location of the renal tumor; the
possibility of recurrence after surgery; the function of their opposite
kidney; possible morbidities; the experience of the surgical team;
and treatment options, including nephron-sparing procedures [47].
If the patient opted to undergo total nephrectomy for a small RCC
after extensive discussion of other possible treatment modalities,
written, informed consent for nephrectomy was obtained. The
possibility of donating the removed kidney for transplantation was
only presented after the patient elected to undergo a nephrectomy.
The potential donors were subsequently approved by the
committee.
From December 2009 to February 2012, 15 patients with renal
tumors gave permission for their resected kidneys to be trans-
planted, and 10 patients were ultimately approved by the commit-
tee. After the patients provided written consent to donate their
kidneys, the possibility of nephron-sparing surgery (NSS) was re-
explained. All of the patients chose to undergo a nephrectomy
despite the potential merit of NSS. To conﬁrm their intentions and
to eliminate coercion, the patients were re-interviewed before sur-
gery by a member of the ethics committee. The patients were
informed by the ethics committee member that they had the right to
refuse nephrectomy at any time before surgery.
The ethics committee at each donor hospital reviewed the pa-
tient criteria according to our checklist and determined their suit-
ability for surgery. The potential donors were then registered with
the Transplant Ofﬁce at Tokyo-West Tokushukai Hospital. The
Restored Kidney Transplant Committee held a meeting for each
patient to review all of the necessary documents and records and to
discuss the donor’s eligibility for inclusion.
Recipient Registration and Selection
Dialysis patients throughout Japan who agreed to undergo restored
kidney transplantation visited Uwajima Tokushukai Hospital for
clinical evaluation. The patients were fully informed about the risk
of cancer transmission and surgical morbidity, and the patients who
accepted the risks and signed a consent form were subsequently
registered with the Tokyo-West Tokushukai Hospital Transplant
Ofﬁce as transplant candidates. A total of 56 dialysis patients ages
31 to 83 years (mean: 58.7 years; 24 in blood group A, 6 in blood
group B, 20 in blood group O, and 6 in blood group AB) and
76 patients ages 34 to 85 years (mean: 61.1 years; 30 in blood group
A, 12 in blood group B, 26 in blood group O, and 8 in blood group
AB) were enrolled as transplant candidates for stages 1 and
2, respectively. Each time a potential donor was registered and
enrolled in the trial, the 5 most suitable transplant candidates with
the same blood group were selected by the Recipient Selection
Committee based on the results of the clinical evaluations using our
selection criteria, which included medical and psychosocial risk
factors [48,49]. The selection of recipients was primarily based on
ABO compatibility and stage 1 clinical scores. Immunological risk
factors (panel reactive antibody and human leukocyte antigen
mismatch) and a history of previous kidney transplantation and
blood transfusion were added as selection criteria for the extended
trial (stage 2) [48]. Cross-matching between the 5 transplant can-
didates and the potential donors was also important for selection
because many patients were highly sensitized, including patients
with a history of transplantation or blood transfusion.
The Restored Kidney Transplant Committee examined the
medical records and consent forms of the 5 transplant candidatesfor each selection and discussed the cases to prioritize transplant
candidates based on the report by the Selection Committee and the
immunological test results. All of the selected candidates were
again informed about donor disease and the possibility of cancer
transmission. After again agreeing to undergo restored kidney
transplantation, the candidate with the highest priority was called
to the hospital to prepare for surgery. The ethics committee of
Uwajima Tokushukai Hospital provided the ﬁnal approval for the
procedures after reviewing all data concerning both the potential
donor and the recipient and the minutes from all committee
meetings.RESULTS
A total of 8 male and 2 female patients 51 to 79 years of age
(mean  SD: 65.3  10.2 years) with small renal tumors
were judged to be suitable kidney donors by the Restored
Kidney Transplant Committee. In addition to these 10 do-
nors, 5 additional potential donors were registered with the
Transplant Ofﬁce. These additional potential donors were
rejected by the committee because of the following protocol
violations: tumor diameter >4 cm in 3 patients, participa-
tion in another clinical trial by 1 patient, and insufﬁcient
renal function because of diabetic nephropathy in 1 patient.
Four donor kidneys were harvested at Uwajima Tokushukai
Hospital, 4 at Kure-Kyosai Hospital, and 1 kidney each at
Kagoshima and Okinawa Chubu Tokushukai Hospitals. The
surgical technique, either laparoscopic or open nephrec-
tomy [41,50], was based on the surgeon experience and
personal preference. Open nephrectomy was chosen for all
patients. Of the 10 donors, 3 were blood group type A,
3 were type B, and 4 were type O. All kidneys had a single
tumor that ranged from 1.5 to 3.9 cm in diameter (Table 1).
The renal tumor was a clear cell carcinoma in 9 patients and
a granular cell carcinoma in 1 patient. All tumors were stage
pT1a in all donors. The RENAL tumor scores ranged from
6 to 9, indicating low-to-moderate complexity [44] (Fig 1).
Blood loss during nephrectomy ranged from 100 to 1000 mL
(433  316 mL). The operating time ranged from 1 hour
and 40 minutes to 5 hours and 15 minutes, and the total
ischemic time ranged from 1 hour and 46 minutes to 9 hours
and 56 minutes, comparable with the results of the EORTC
intergroup phase 3 study [51]. The tumor was excised with
an adequate border (1 cm) of healthy parenchyma [52].
Upon arrival at the transplanting hospital, the kidney was
conﬁrmed to be cancer-free according to the pathological
report of the cut surface provided by the donor hospital. As
soon as the kidney arrived at Uwajima Tokushukai Hospital,
the cut surface was sutured and repaired on the second
table, which required 5 to 53 minutes. The ﬁfth kidney had a
positive margin, requiring additional resection to be cancer-
free. The frozen sections were similar to the ﬁnal pathology
in all cases. The restored kidneys were transplanted into
10 unrelated recipients ages 46 to 66 years (Table 2). The
transplantation procedure lasted between 1 hour and
56 minutes and 3 hours and 39 minutes (Table 3). The
donor kidney from a blood group B patient was transplanted
into an AB recipient in the seventh case because no suitable
Table 1. Characteristics of Donor Patients and Tumors, including Blood Type, Renal Function, Latest Most Recent Serum Creatinine,
Tumor Size, and RENAL Nephrometry Score
Case Number,
Age, Sex ABO, Rh
eGFR/DTPA-GFR of
Donor Kidney (mL/min)
Latest Serum
Creatinine (mg/dL)
Tumor Diameter
(cm)
RENAL Nephrometry
Score
PADUA
Score C Index
1. 51 y, M B Rh(þ) 76/30.32 1.30 3.9 6 6 2.7
2. 57 y, M O Rh(þ) 88/44.69 1.17 3.5 6 8 2.4
3. 79 y, M O Rh(þ) 40/27.84 4.68 2.0 6 9 2.1
4. 61 y, M B Rh(þ) 64/34.62 1.65 3.5 7 9 1.6
5. 69 y, M A Rh(þ) 62/22.80 1.45 3.8 7 10 1.9
6. 71 y, M A Rh(þ) 68/36.62 1.02 3.8 8 10 2.0
7. 77 y, F B Rh(þ) 55/26.92 1.11 2.4 6 9 3.9
8. 64 y, M O Rh(þ) 103/45.85 0.84 3.5 8 9 2.3
9. 73 y, M A Rh(þ) 73/42.00 1.21 3.7 9 11 2.5
10. 51 y, F O Rh(þ) 66/35.86 0.98 1.5 6 7 4.5
RENAL, radius, exophytic/endophytic properties, nearness to a collecting system or sinus, anterior/posterior, location relative to polar lines; eGFR, estimated
glomerular ﬁltration rate; DTPA, diethylene triamine pentaacetic acid; M, male; F, female.
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performed in the right iliac fossa in 6 recipients. In 4 re-
cipients who previously underwent transplantation, trans-
plantation was performed in the left iliac fossa (Table 3).
Four recipients required blood transfusion (4 to 6 units)
during transplantation. A retroperitoneal hematoma
developed in the sixth recipient, but no other major peri-
operative complications (hematoma or urinoma) were
noted. All 10 recipients received triple-agent immunosup-
pression that was gradually tapered. In stage 1, 4 recipients
survived an accelerated acute rejection that required plasma
exchange and hemodialysis. Some of these patients subse-
quently experienced more rejection episodes. Three pa-
tients experienced multiple SAEs. One patient (no. 4)
survived 6 SAEs, and the graft functioned well until
35 months after surgery. However, this patient died of car-
diac failure because of arrhythmia and chronic renal failure
40 months after surgery. Among stage 2 patients, 4 re-
cipients experienced rejection episodes but did not require
hemodialysis. The most recent serum creatinine levels
ranged from 1.10 to 3.19 mg/dL in the 9 surviving recipients
and from 0.84 to 4.68 mg/dL in the 10 donor patients
(Tables 1 and 4). RCC recurrence was not noted during the
follow-up period (32 to 58 months) in either the recipients
or the donor patients (Table 4).
In the third donor (79 years of age), kidney function
worsened, and the serum creatinine level was 4.68 mg/dLFig 1. Sizes and locations of the
10 renal tumors.4 years and 5 months after nephrectomy. In the recipient
(62 years of age), kidney function improved, and the
serum creatinine level was 2.04 mg/dL 4 years and 5
months after transplantation. The restored kidneys from
donors ages 71 to 79 years continue to function well in
recipients ages 46 to 62 years. In these recipients, the
serum creatinine levels ranged from 1.10 to 2.37 mg/dL at
36 to 53 months after transplantation, suggesting that
kidneys from donors over 70 years old are not necessarily
of poor quality.DISCUSSION
Kidney transplantation is generally regarded as the treat-
ment of choice for end-stage renal disease with respect to
survival, quality of life, and cost [53e56]. Graft survival rates
and other long-term outcomes are similar for elderly
patients and patients younger than 60 years. Thus, the
presence of comorbidities should be the only clinical crite-
rion for excluding elderly patients as kidney transplant
candidates [57]. The projected life expectancy after
transplantation is 17 to 19 years, compared with only
5.84 years for patients on dialysis [58e61]. On average, re-
cipients of marginal kidney transplants live 5 years longer
than dialysis patients on the transplant waiting list, whereas
ideal deceased kidney recipients gain a 13-year survival
beneﬁt [62].
Table 2. Recipient Demographic Factors, Including Blood Type, Renal Pathology, Duration of Hemodialysis/Peritoneal Dialysis,
Transplant History, and Duration of Graft Function
Case Number,
Age, Sex ABO, Rh Renal Pathology
HD/PD
Duration
Transplantation
History
Graft Survival
(Transplantation Date)
1. 47 y, F B Rh(þ) Immunoglobulin A nephropathy 10 mo None 4y, 10 mo (Dec. 30, 2009)
2. 54 y, F O Rh(þ) CGN 1 y, 9 mo None 4 y, 6 mo (Apr. 6, 2010)
3. 62 y, F O Rh(þ) PKD 1 y, 4 mo 8 y 4 y, 5 mo (Apr. 27, 2010)
4. 66 y, M B Rh(þ) DM nephropathy 3 y, 10 mo 3 y 4 y, 2 mo (Jul. 24, 2010)
5. 55 y, F A Rh(þ) CGN 3 y, 7 mo None 4 y, 1 mo (Aug. 24, 2010)
6. 46 y, M A Rh(þ) RPGN 9 y, 11 mo None 3 y, 9 mo (Jan. 12, 2011)
7. 56 y, F AB Rh(þ) CGN 1 y, 9 mo None 3 y, 8 mo (Jan. 30, 2011)
8. 65 y, F O Rh(þ) PKD 14 y None 3 y, 4 mo (Jun. 1, 2011)
9. 54 y, M A Rh(þ) CGN 9 y, 5 mo 1 mo 3 y, 0 mo (Sept. 14, 2011)
10. 56 y, F O Rh(þ) CGN 8 y, 5 mo 2 y, 10 mo 2 y, 8 mo (Feb. 13, 2012)
HD, hemodialysis; PD, peritoneal dialysis; CGN, chronic glomerulonephritis; PKD, polycystic kidney disease; DM, diabetes melitis; RPGN, rapidly progressive
glomerulonephritis.
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“unrescuable” dialysis patients waiting for transplantation,
thus only 14 of 42 patients (33.3%) received a primary
transplantation in their series [3]. Urologists manage not
only patients in need of renal transplantation but also pa-
tients who require nephrectomy for various diseases. Thus,
Mannami et al. chose to transplant kidneys that would
otherwise have been discarded into dialysis patients in need
of renal transplantation [3]. Our prospective trial was
designed based on this concept for rescuing high-risk pa-
tients, eg, patients in whom arteriovenous ﬁstulas are difﬁ-
cult to create and who require a second or third
transplantation.
Restored kidney transplantation involves a nephrectomy,
an ex vivo partial nephrectomy with restoration, and trans-
plantation. The entire procedure is demanding and
complicated; an understanding of and experience with these
specialized procedures is required. Donor nephrectomy may
be associated with bleeding requiring blood transfusion, and
restored kidney transplantation complications include peri-
nephric hematoma, calyceal ﬁstula, and arteriovenous
ﬁstula [4].
Transplant surgeons often inform their patients that living
donor transplants are typically safe and provide an extendedTable 3. Details of Donor Nephrectomy and Transplantation Surger
and Trans
Case
Number Histopathology
Donor
Nephrectomy
Blood Loss
(mL)
Is
1. Clear cell RCC, G2 5h 15 min 800 6 h
2. Clear cell RCC, G1 3 h 0 min 153 1 h
3. Clear cell RCC, G2 3 h 43 min 237 3
4. Clear cell RCC, G2 1 h 52 min 230 3
5. Granular RCC, G3 2 h 8 min 800 8 h
6. Clear cell RCC, G2 4 h 45 min 1000 7 h
7. Clear cell RCC, G2 1 h 59 min 419 2
8. Clear cell RCC, G2 4 h 55 min 100 7 h
9. Clear cell RCC, G2 4 h 20 min 300 6 h
10. Clear cell RCC, G1 1 h 40 min 290 9 h
RCC, renal cell carcinoma.better quality of life for the recipient. However, the use of
living donors raises an ethical dilemma because organ
donation has the potential to cause harm to the healthy
living donor. The perioperative mortality rate after living
donor nephrectomy is 0.03%. The morbidity rate, including
minor complications, is approximately 10% [63]. The con-
sequences of being a living donor have proven to be excel-
lent, and living donors can have better outcomes than their
population counterparts [64e67]. The 30-day mortality rate
after nephrectomy for RCC was 0.9% in an entire cohort of
24,535 patients (Surveillance, Epidemiology, and End Re-
sults [SEER] database), and the foremost determinants of
mortality were age and tumor stage [68]. Despite the in-
crease in morbidity and mortality typically observed in
elderly patients [69], we found that restored kidneys from
donors over 70 years old continued to function properly in
4 recipients, demonstrating encouraging results for the
utility of transplanted kidneys from elderly donors. In the
United States, 219 living kidney donors over 70 years old
had an excellent 10-year overall survival rate (56.2%) [70],
suggesting that transplantation from live donors over
70 years old can be beneﬁcial with appropriately selected
donor-recipient pairs [71e78]. The risk of transmitting a
small RCC by restored kidney transplantation (0.015% toy, Including Tumor Histopathology, Operating Time, Blood Loss,
fusion
chemic
Time Restoration
Transplant
Time Blood Transfusion
24 min 10 min 1 h 56 min None
46 min 20 min 3 h 12 min None
h 4 min 53 min 3 h 39 min 4 units
h 8 min 33 min 2 h 38 min None
26 min 45 min 2 h 25 min 4 units
53 min 29 min 3 h 26 min 4 units þ albuminate 7
h 8 min 21 min 2 h 17 min albuminate 2
19 min 23 min 1 h 57 min 6 units þ FFP 4 units
46 min 9 min 2 h 50 min None
56 min 5 min 3 h 14 min None
Table 4. Transplantation Outcomes, Including Baseline Clinical Scores, Cross-Matching and HLA Compatibility, Latest
Immunosuppression, Latest Serum Creatinine, Acute Rejection, and Serious Adverse Events
Case Number,
Age, Sex Clinical Score
HLA Compatibility Cross-Match
Tw/Tc/Bw/Bc
Latest
Immunosuppression
Latest Serum
Creatinine
Acute
Rejection
SAE
Excluding AR
1. 47 y, F 75.16/104 0/5/0/0 MMF 1000 mg
TAC 4 mg
1.34 1 2 (FUO, CMV)
2. 54 y, F 76.37/104 0/0/0/0 MMF 500 mg
TAC 5 mg
1.22 0 0
3. 62 y, F 75.35/104 5/0/0/5 MMF 500 mg
TAC 2 mg
2.04 1 0
4. 66 y, M 78.15/104 0/0/0/0 HD at 35 m Died at 40 m 3 6 (pneumonia, leucopenia,
nephrosis, anemia, CMV)
died of MI on
Jan. 28, 2014
5. 55 y, F 79.71/104 5/5/0/0 MMF 500 mg
TAC 4 mg
PSL 10 mg
3.19 3 4 (UTI, abscess, leucopenia)
6. 46 y, M 66/76 Tw/Tc/Bw/Bc/PRA/
Mismatch 0/0/0/0/
Class I-class II -/4
MMF 1000 mg
TAC 6 mg
PSL 10 mg
2.37 1 1 (CMV)
7. 56 y, F 71/76 0/0/0/0/þ -/6 MMF 500 mg
TAC 5 mg
PSL 10 mg
2.04 1 2 (leucopenia, proteinuria)
8. 65 y, F 64/76 0/0/0/0/- -/3 MMF 500 mg
TAC 2 mg
1.12 0 2 (FUO)
9. 54 y, M 66/76 5/5/0/0/þ þ/6 MMF 500 mg
TAC 2 mg
1.10 2 1 (CMVþBKV)
10. 56 y, F 66/76 5/0/5/15/- -/4 MMF 1000 mg
TAC 5 mg
1.75 2 0
HLA, human leukocyte antigen; Tw, T warm; Tc, T cold; Bw, B warm; Bc, B cold; MMF, mycophenolate mofetil; TAC, tacrolimus; PSL, prednisolone; AR, acute
rejection; SAE, serious adverse event; FUO, fever of unknown origin; CMV, cytomegalovirus infection; MI, myocardial infarction; BKV, BK virus infection.
1716 OGAWA, KOJIMA, MANNAMI ET AL1%) seems insigniﬁcant compared with the perioperative
mortality rates for nephrectomy (0.03% for living donor
nephrectomy and 0.3% to 1.7% for nephrectomy to remove
RCC) and transplantation (1.7%).
A systematic review indicated that NSS results in signiﬁ-
cantly enhanced preservation of renal function compared
with radical nephrectomy (RN). This evidence cannot be
considered conclusive because of the inclusion of low-
quality studies with a high risk of bias [79e81]. Only 1 pro-
spective randomized study, conducted by the European
Organisation for Research and Treatment of Cancer group,
compared RN and NSS for RCC in 541 patients with
tumors <5 cm in diameter and a normal contralateral kid-
ney. This study provided the ﬁrst level 1 evidence that both
surgical procedures achieve excellent oncological results.
Furthermore, the 10-year overall survival rate was signiﬁ-
cantly enhanced after RN compared with NSS [82]. The
potential protective effect of NSS on noncancer mortality
remains controversial [51,83e87]. Whether NSS is a suitable
technique for older patients with T1 renal tumors in a
general urology practice remains to be determined [88,89].
If a patient has renal cancer, the risk of harm from the
operation is typically outweighed by the beneﬁt of removing
the tumor, which might otherwise spread and kill the patient.
A kidney restored by resection of a small RCC could be
considered amarginal organ because its volume is reduced by
tumor resection. Thus, kidneys with satisfactory function thatare removed because of other diseases might also warrant
consideration for selected patients. Tsutsumi (2009) esti-
mated that 2000 kidneys are discarded in Japan each year,
and the use of these organs raises fewer ethical issues than
using kidneys from healthy living donors [27]. Questionnaire
surveys conducted by the Japan Urological Association in
2010 and by the Japanese Ministry of Health, Labor, and
Welfare in 2012 conﬁrmed that the estimate by Tsutsumi
seems reasonable [90]. In the USA, nearly 3000 kidneys
could be made available for transplantation annually [21,91].
Cooperberg et al. reported that the number of patients with
stage I disease in the United States increased to 14,176 in
2007. Among these patients, 57.7% received a total ne-
phrectomy, and 1809 kidneys with RCCs <2.5 cm were
removed [92]. In theUK, approximately 7000 newRCC cases
are diagnosed each year, and more than half are stage T1a
tumors treated by radical nephrectomy [93]. Urologic on-
cologists should have discussions with transplant surgeons
about kidney transplantation in selected recipients after
ex vivo excision of small masses from selected donors [25].
We used the RENAL nephrometry system, which is
useful for surgeons for both preoperative and intraoperative
decision making. The nephrometry score provides a useful
tool for objectively describing renal mass characteristics and
enhancing operative planning regarding renal masses. Our
ninth donor had a small renal tumor (3.7 cm), and the
surgeons cut superﬁcially 1 cm around the tumor. However,
TRANSPLANTATION OF RESTORED KIDNEYS 1717re-excision because of a positive surgical margin was per-
formed three times because the tumor capsule was not well
developed. The tumor was entirely endophytic, and its
texture was similar to the normal parenchyma. This endo-
phytic tumor without a clear capsule illustrates the possible
difﬁculty of identifying the tumor margin within a short time
period at the time of partial nephrectomy. Positive surgical
margins are present in 0% to 7% of patients after open
NSS, 0.7% to 4% of patients with positive surgical margins
after NSS remain disease-free, and surveillance is preferable
to surgical re-intervention [94e100].
Nicol et al. suggested that transplant units should estab-
lish connections with their urologist colleagues [4]. Meng
et al. proposed a system of utilizing a multidisciplinary team
approach for planned transplantations of restored kidneys
after tumor excision [91]. The Western Australia Group
initiated a new program in which local urologists are
encouraged to contact the transplantation service when
considering RN, and recipients are selected according to
strict criteria [101]. Equal access criteria (UNOS 2001)
include wait time, age, organ type, blood type, organ size,
distance from donor to patient, and medical urgency [102].
In addition, organs should be distributed on the basis of
maximum beneﬁt despite bias, lying, favoritism, and other
unfair practices. Maximizing years of life should be the most
important criterion for the distribution of organs [103].
In conclusion, carefully selected patients can tolerate
restored kidney transplantation, and good renal function can
be achieved without tumor recurrence. Various lessons were
learned from our prospective trial, which implies a national
project necessary to organize transplant surgeons and urol-
ogists to work together for restored kidney transplantation.
The use of living donors seems to offer the best solution to
the organ shortage problem [104]. Therefore, kidneys with a
small renal tumor in potential living donors should be used
for transplantation [105], most likely leading to better un-
derstanding this kind of procedure. Restored kidneys from
donors over 70 years old can function well, providing another
source of donor kidneys, especially between an elderly
couple. High-risk recipients tend to have immunological risk
factors because of long-term hemodialysis, previous trans-
plantation, and/or blood transfusion. The inclusion of high-
risk patients may be associated with the high incidence of
rejection episodes, which needs further study. Therefore,
further studies deﬁning the most suitable high-risk recipients
for this procedure and using new immunosuppressants to
prevent cancer transmission and reduce rejection episodes
are warranted [9]. Importantly, care must be taken to avoid
cancer transmission and to ensure fair recipient selection,
close follow-up, and a well-organized tracking system.
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